Optimi Health (CSE: OPTI) has recently introduced Blue Serenity, the first natural therapeutic psilocybin product in Canada, in collaboration with psilocybin patient advocate, Thomas Hartle.
Blue Serenity contains 25 milligrams of natural psilocybin in the form of EU-GMP biomass grown as Panaeolus cyanescens mushrooms, which were cultivated at Optimi Health’s facilities in Princeton, British Columbia. Optimi’s chief science officer, Justin Kirkland, and head of cultivation, Todd Henderson, partnered with Mr. Hartle to develop a specific genetic strain based on his therapeutic experiences.
The partnership was announced on August 8, with Optimi Health expressing its commitment to producing a Canadian-grown and harvested natural therapeutic psilocybin product for patient use. CEO Bill Ciprick emphasized the importance of patient advocates like Mr. Hartle in driving breakthroughs in the industry.
Blue Serenity will soon be available to legal psilocybin patients approved by Health Canada. Mr. Hartle, who was the first Canadian to receive psilocybin-assisted psychotherapy legally in 2016, has seen significant improvements in his emotional well-being and overall quality of life as a result.
Research indicates that a large percentage of patients facing advanced stage cancer or incurable conditions experience distressing thoughts and psychiatric diagnoses. Mr. Hartle’s experience with psilocybin therapy inspired the naming of Optimi’s new product, ‘Blue Serenity’, reflecting the calming and transformative effects of his own journey.
The proceeds from the sale of Blue Serenity will support underserved adults in accessing psilocybin therapy through Mr. Hartle’s charity.
